Drug Trial Radar · NCT07898371
A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world Setting
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Sep 21, 2031
Study completion Oct 1, 2031
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 27, 2026
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to assess the real-world treatment patterns, data from patient reported outcomes, the effectiveness profile of tolebrutinib, and health care utilization data in routine practice. The decision to initiate tolebrutinib treatment is made by the treating neurologist as part of standard of care. Consideration and option of participation in the study will only be done once the treatment decision has been made, independent of study participation. Only upon signing the informed consent form (ICF) will the patient be enrolled in the study. The patient's participation in the study will not influence the MS treatment. Total study duration of study is 5 years per country comprising an approximately 24-months of enrollment period followed by a 36-month individual observational period.
Conditions
- Multiple Sclerosis
Interventions
TolebrutinibDrug
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Socio-demographic CharacteristicsTime frame: Baseline
- Disease History: Most Recent Disability Status Scale (EDSS) scoreTime frame: Baseline
- Disease History: EDSS Progression in Past 12 MonthsTime frame: Baseline
- Disease History: Time Since Relapsing-Remitting Multiple Sclerosis (RRMS) Symptom OnsetTime frame: Baseline
- Disease History: Time Since Secondary Progressive Multiple Sclerosis (SPMS) DiagnosisTime frame: Baseline
- Disease History: Time Since Most Recent Clinical RelapseTime frame: Baseline
- Disease History: Number and Type of Previous MS TreatmentsTime frame: Baseline
- Disease History: Number and Type of Prior and Current Disease Modifying Therapies (DMTs)Time frame: Baseline
- Disease History: Number of Participants with ComorbiditiesTime frame: Baseline
- Disease History: Number of Participants with Medical HistoryTime frame: Baseline
- Disease History: Number of Participants with Concomitant MedicationTime frame: Baseline
- Magnetic Resonance Imaging DataTime frame: Baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harley Street Medical Centre
Marina, Abu Dhabi Emirate, United Arab Emirates · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.